$HIMS fell 14% today even after an FDA recommended expanding access to 6 of the 7 peptides reviewed. The broader market was red today, but I also don’t think the market has fully digested the good news yet. This looks like an overreaction. https://t.co/qwNedRqTgn
在 X 查看 ↗